Patients who experienced disease progression on dabrafenib alone were able to cross over into the combination treatment arm. (sciencedaily.com)
Researchers have identified characteristics associated with improved outcomes when treating BRAF - mutated advanced melanoma with the combination of dabrafenib and trametinib. (cancernetwork.com)
Several agents that directly target BRAF have been approved by the Food and Drug Administration for the treatment of melanoma patients who have the mutation, including dabrafenib and vemurafenib. (sciencedaily.com)